MDXG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
MiMedx Group Inc (MDXG) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and growth potential outweigh the near-term uncertainties. The recent share repurchase program and record earnings further support the investment case.
The MACD is positive and contracting, indicating a potential upward momentum. RSI is neutral, suggesting no overbought or oversold conditions. The current price is near the support level of $4.897, offering a favorable entry point. Moving averages are converging, indicating consolidation.
Record Q4 2025 earnings with a 27% YoY revenue increase.
Initiation of a $100 million share repurchase program.
Positive long-term growth prospects in the surgical recovery business and potential market share gains in wound care.
Analysts maintain a Buy/Outperform rating with price targets significantly above the current price.
Near-term uncertainty due to CMS reimbursement changes and provider confusion.
Slower volume momentum expected in Q1
Recent price target reductions by analysts, though still higher than the current price.
In Q4 2025, revenue increased by 27.11% YoY to $118.1 million. Net income grew by 104.24% YoY to $15.19 million. EPS doubled to $0.10, and gross margin improved to 83.76%. These figures highlight strong financial growth and operational efficiency.
Analysts maintain a generally positive outlook with Buy/Outperform ratings. Price targets range from $8 to $13, indicating significant upside potential from the current price. Analysts acknowledge near-term challenges but highlight long-term growth opportunities in surgical recovery and wound care.
